StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Free Report) in a report published on Wednesday. The firm issued a hold rating on the stock.
Trinity Biotech Trading Down 2.9 %
Shares of NASDAQ:TRIB opened at $0.73 on Wednesday. The stock has a fifty day simple moving average of $0.85 and a two-hundred day simple moving average of $1.30. The stock has a market capitalization of $13.20 million, a price-to-earnings ratio of -0.32 and a beta of 1.03. Trinity Biotech has a 12-month low of $0.72 and a 12-month high of $3.55.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its holdings in Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 7.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 359,810 shares of the company’s stock after purchasing an additional 26,100 shares during the quarter. Hunter Associates Investment Management LLC owned 4.72% of Trinity Biotech worth $390,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 78.97% of the stock is owned by institutional investors.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Read More
- Five stocks we like better than Trinity Biotech
- What Is WallStreetBets and What Stocks Are They Targeting?
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- What Investors Need to Know About Upcoming IPOs
- 5 Best Gold ETFs for March to Curb Recession Fears
- What is the Nikkei 225 index?
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
